✅Rob Fia, CEO of Therma Bright-Documents Submitted
(A few weeks are gone). November 12, 2021. Based on current COVID-19 infection rates, we expect the study results to be delivered to the FDA within the next few weeks, as part of our AcuVid application for Emergency Use Authorization (EUA). More info at: https://themarketherald.ca/therma-bright-to-begin-acuvidtm-u-s-clinical-performance-study-with-receipt-of-irb-conditional-approval-2021-11-12/